Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric-inspired BFM-2000 chemotherapy for adolescents and young adults with newly diagnosed acute lymphoblastic leukemia
ACTRN12611000814976Phase 2Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Sep 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of methotrexate, prednisolone, vincristine, daunorubicin, pegaspargase and 10 more in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Feasibility of delivering modified BFM-2000 in a pediatric-comparable timeframe. Started Sep 2012; status: completed.
02
Drugs
methotrexateprednisolonevincristinedaunorubicinpegaspargase
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ACTRN12611000814976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000814976.